DBT, BIRAC To Convene Industry–Academia Meet On Cell & Gene Therapy Roadmap

New Delhi, Nov 3 (KNN) The Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC) will host a high-level Industry–Academia Stakeholders’ Meet on the future of cell and gene therapy (CGT) on November 6, 2025, in New Delhi. 

The meeting, titled ‘The New Frontier: Innovation, Regulation and Access in Cell and Gene Therapy’, will bring together senior government officials, scientific experts, industry leaders and clinicians to chart a roadmap for advancing India’s CGT ecosystem.

Discussions will focus on developing an enabling regulatory framework, strengthening translational research capabilities, and ensuring safe, equitable and timely access to CGT-based treatments. 

Senior representatives from the Central Drugs Standard Control Organisation (CDSCO), the Indian Council of Medical Research (ICMR), the Department of Pharmaceuticals, DBT and BIRAC are expected to participate.

The meeting will also see participation from leading global and domestic stakeholders, including ImmunoACT, Miltenyi Biotec, Novartis, Immuneel Therapeutics, AIIMS, the Centre for Stem Cell Research, and Bric-InStem, among others.

A key agenda item will be advancing work toward a National Policy Mission for Cell and Gene Therapy to strengthen domestic research and manufacturing capabilities and establish streamlined regulatory pathways in this emerging field. 

The initiative seeks to position India as a competitive global player in precision medicine, supporting access to advanced therapies for conditions such as genetic disorders, cancers and rare diseases.

Through collaborative deliberations, the event aims to accelerate the growth of India’s biotechnology landscape and bolster national capacity in cell and gene therapy development and delivery.

(KNN Bureau)